

REVIEW

Gastrointestinal and Hepatic Complications of Sickle Cell Disease

ELLEN C. EBERT,* MICHAEL NAGAR,† and KLAUS D. HAGSPIEL‡

*Department of Medicine and †Department of Pathology, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, New Jersey; and ‡Department of Radiology, University of Virginia Health System, Charlottesville, Virginia

This article has an accompanying continuing medical education activity on page e70. Learning Objectives—At the end of this activity, the learner should be able to identify the main intra-abdominal complications of sickle cell disease and explain the reason for their occurrence.

Sickle cell disease (SCD) is an autosomal recessive abnormality of the β -globin chain of hemoglobin (Hb), resulting in poorly deformable sickled cells that cause microvascular occlusion and hemolytic anemia. The spleen is almost always affected by SCD, with microinfarcts within the first 36 months of life resulting in splenic atrophy. Acute liver disorders causing right-sided abdominal pain include acute vaso-occlusive crisis, liver infarction, and acute hepatic crisis. Chronic liver disease might be due to hemosiderosis and hepatitis and possibly to SCD itself if small, clinically silent microvascular occlusions occur chronically. Black pigment gallstones caused by elevated bilirubin excretion are common. Their small size permits them to travel into the common bile duct but cause only low-grade obstruction, so hyperbilirubinemia rather than bile duct dilatation is typical. Whether cholecystectomy should be done in asymptomatic individuals is controversial. The most common laboratory abnormality is an elevation of unconjugated bilirubin level. Bilirubin and lactate dehydrogenase levels correlate with one another, suggesting that chronic hemolysis and ineffective erythropoiesis, rather than liver disease, are the sources of hyperbilirubinemia. Abdominal pain is very common in SCD and is usually due to sickling, which resolves with supportive care. Computed tomography scans might be ordered for severe or unremitting pain. The liver typically shows sickled erythrocytes and Kupffer cell enlargement acutely and hemosiderosis chronically. The safety of liver biopsies has been questioned, particularly during acute sickling crisis. Treatments include blood transfusions, exchange transfusions, iron-chelating agents, hydroxyurea, and allogeneic stem-cell transplantation.

Keywords: Liver Disease; Gallstones; Abdominal Pain.

Sickle cell disease (SCD) is an autosomal recessive abnormality of the β -globin chain of hemoglobin (Hb) that changes the sixth amino acid from glutamic acid to valine.¹ The resulting Hb S polymerizes reversibly when deoxygenated to form a gelatinous network that stiffens the erythrocyte membrane and increases viscosity, producing the characteristic sickle shape. Such sickled cells lose flexibility needed to traverse small capillaries and have “sticky” membranes that adhere to the

endothelium of small venules. These abnormalities result in microvascular occlusion and red blood cell destruction.

The heterozygous sickle trait is found in 8%–10% of the African American population.¹ Less commonly, Hb S combines with either Hb C or β -thalassemia. Fetal Hb F, which accounts for 80% of the Hb concentration at birth, declines to less than 1% by 6 months. It interferes with Hb S polymerization, and its concentration directly correlates with improvement in disease severity and prognosis. Hydroxyurea, which increases the concentration of Hb F, ameliorates the severity of painful crises in SCD.

The Spleen in Sickle Cell Disease

The spleen is almost always involved in SCD (Figure 1). It is usually infarcted within the first 18–36 months of life, paralleling the disappearance of protective Hb F, resulting in hyposplenism or asplenism.² Splenic atrophy increases susceptibility to infection with encapsulated bacteria. The onset of functional asplenia is reflected by the appearance of irreversibly sickled cells, anisocytosis, Howell-Jolly bodies, and siderocytes.

Splenic infarction caused by occlusion of the small splenic vessels from sickling is the most common in patients with sickle cell (SC)-Hb C or SC-thalassemia disease.³ This is due to the near-normal Hb levels that produce a relatively high blood viscosity and to splenomegaly found in a majority of adults with these diseases. It might also occur with SC trait even in nonhypoxic conditions.⁴ Splenic infarction presents with left upper quadrant pain, nausea and vomiting, a friction rub over the splenic area, and leukocytosis. With resolution of splenic abscesses or infarcts, pseudocysts might develop.⁵

Sequestration syndrome, or the rapid pooling of blood, usually affects the pulmonary circulation. Before the development of hyposplenism, it can cause rapid splenic enlargement and a drop in Hb.⁶ In homozygous SCD, sequestration occurs in infants and children because progressive fibrosis of the spleen

Abbreviations used in this paper: CDL, choledocholithiasis; CT, computed tomography; Hb, hemoglobin; LDH, lactate dehydrogenase; MRI, magnetic resonance imaging; SCD, sickle cell disease.

© 2010 by the AGA Institute

1542-3565/\$36.00

doi:10.1016/j.cgh.2010.02.016




Figure 1. A 47-year-old woman with SCD and history of autosplenectomy. Unenhanced CT of the abdomen (A) shows increased density of the small spleen. On MRI (B) the spleen is also small and diffusely hypointense on all sequences, consistent with findings of dense calcification on CT. The calcifications and small size make detection of the spleen difficult on ultrasound.

impairs its ability to sequester blood. In SC-thalassemia, on the other hand, sequestration might occur at any age because the spleen is chronically enlarged. Hypovolemic shock and death might occur within hours if not prevented by transfusions. Occasionally, the organ might rupture. Splenomegaly might also be due to extramedullary hematopoiesis or to hemosiderosis.⁵

The Liver in Sickle Cell Disease

Acute Processes

There are several causes of right upper quadrant pain as it specifically relates to SCD. In patients admitted for acute vaso-occlusive crisis (severe pain in chest, abdomen, and joints), the liver is involved in about 39% of cases.⁷ These patients present with abdominal meteorism, right upper quadrant pain, or acute painful hepatomegaly. The type of liver injury is usually cholestatic or mixed rather than purely hepatocellular, usually with normal synthetic function.

Liver infarction in SCD has been observed in 34% of autopsies.⁸ In half of these cases, an associated cause of infarction (cardiac dysfunction or sepsis) is present. The resulting high blood viscosity predisposes to infarction despite the dual blood supply of the liver. Infarction might also occur in those with SC trait⁹ or SC-Hb C disease.¹⁰

Acute sickle hepatic crisis affects about 10% of patients admitted for painful crisis.¹¹ It simulates acute cholecystitis with right upper quadrant pain, fever, leukocytosis, and variable increases in serum transaminases and bilirubin levels. The AST and ALT levels are usually 1–3 times normal,¹² although levels of greater than 1000 IU/L have been reported.¹³ Unlike cholecystitis, the liver is usually enlarged and tender.

An uncommon complication is acute hepatic sequestration with jaundice and right upper quadrant pain associated with an enlarged liver and a drop in hematocrit accompanied by an appropriate reticulocytosis.^{14,15} This is thought to be due to obstruction of sinusoidal flow by masses of sickled erythrocytes, trapping them in the liver. With resolution of the sinusoidal obstruction, erythrocytes might return to the circulation, causing a rapid rise in Hb; this suggests that not all sequestered cells are destroyed. The result can be death as a result of hypervolemia, heart failure, and intracerebral hemorrhage.¹⁶

A rare but potentially fatal complication known as SC intrahepatic cholestasis is thought to represent an unusually severe

form of hepatic crisis.^{17,18} There is widespread sickling in the sinusoids, resulting in hepatic ischemia. It is characterized by right upper quadrant pain, nausea, vomiting, tender hepatomegaly, and leukocytosis. There is extreme hyperbilirubinemia (from hemolysis, intrahepatic cholestasis, and renal impairment), with the conjugated fraction exceeding 50% of the total. In addition, there is a modest elevation of transaminase levels and coagulopathy. Patients die of liver failure and/or a hemorrhagic diathesis.

Rarely, liver abscesses occur as a result of diminished removal of bacteria from the bloodstream as a result of functional asplenicism and reduced IgG antibodies to polysaccharide antigens.¹⁹ It should be considered in a patient with fever and right upper quadrant pain and might represent a secondarily infected hepatic infarct.²⁰ Rarely, the liver abscess is due to *Yersinia enterocolitica* because iron overload and desferrioxamine therapy increase susceptibility to this organism.²¹

The clinical course of acute hepatitis B in patients with SCD might be the same as in control patients²² or marked by higher bilirubin levels.¹¹ Seropositivity for hepatitis B surface antigen in SC patients is up to 3.3% of the population in the United States.²³ Vaccination against hepatitis B has been shown to be effective in SC patients.²⁴

A hepatic bile-filled cyst (biloma), presumably the result of a hepatic infarction, has been described in a patient with right upper quadrant pain, fever, and jaundice.²⁵ Cocaine hepatotoxicity has been described in a patient in SC crisis.²⁶ The patient subsequently developed hepatic failure, which is rare in SCD. Occasionally, large vessel obstruction of the hepatic or portal veins^{27,28} has been encountered in SCD.

Chronic Processes

Chronic liver disease in SCD might be due to hemosiderosis and hepatitis. It is possible that repeated small, clinically silent microvascular occlusions occur throughout the life of an SCD patient, eventually leading to liver fibrosis, superimposed on other causes of chronic liver disease. The high rate of liver cirrhosis of 18% among young patients with SCD, causing death in 11% of cases, supports this view.^{29,30}

With increased longevity of patients with SCD, iron overload has become an issue. It stems from accumulation of transfused iron, increased gastrointestinal absorption as a result of intensive erythropoiesis, and iron deposition as a result of continu-

Figure 2. Gomori's iron stain. (A) Liver; original magnification, 20 \times . Hepatocytes show diffuse severe iron deposition. Kupffer cells show strong reactivity to iron. (B) Liver; original magnification, 400 \times . Dilation and filling of sinusoids with sickled red blood cells in aggregates. Marked hepatocellular cytoplasmic iron deposition (grade 3 siderosis) is probably related to chronic transfusions.

ous hemolysis. The iron is deposited in the reticuloendothelial system, including the Kupffer cells (Figure 2).

Hepatitis C was prevalent in this highly transfused population before the screening of blood products.²³ In thalassemia, interferon and ribavirin resulted in a sustained virologic response of 45%.³¹⁻³³

Focal nodular hyperplasia is characterized by nodules of regenerative hepatocytes distributed diffusely throughout the liver, with atrophy of the intervening parenchyma.^{34,35} Minimal fibrosis and lack of hepatic dysfunction differentiate it from cirrhosis. It might be due to obstructive portal venopathy with areas of compromised blood flow.

Patients with SCD might develop zinc deficiency as a result of increased renal loss of zinc³⁶ and increased fecal loss with deferoxamine therapy.³⁷ Zinc deficiency might result in elevated ammonia levels because the urea cycle is inhibited by the absence of zinc, a cofactor for this pathway. This elevation of ammonia can theoretically worsen hepatic encephalopathy and can be corrected by zinc therapy.³⁸ Zinc supplementation also decreases the number of pain crises in these patients.³⁹

The Gallbladder in Sickle Cell Disease

Cholelithiasis, diagnosed by ultrasound, is found in 26%–58% of SCD patients versus 17% in patients with SC-Hb C disease and SC- β -thalassemia⁴⁰⁻⁴² (Figure 3). Those with stones have a higher mean bilirubin level than those without stones.⁴² Gallstones are typically of the black rather than brown pigment type as a result of elevated bilirubin excretion. About 50% of them can be seen on plain films because the bilirubin is typically in the form of its calcium salt.^{43,44} With increasing age, cholesterol gallstones might develop.

The incidence of choledocholithiasis (CDL) in SCD with cholelithiasis has been described as being more than or equal to that found in patients with cholesterol gallstones,^{45,46} ranging from 19%–26%. The smaller size of the bilirubin compared with cholesterol gallstones might permit them to move more readily from the gallbladder into the common bile duct. Because of their small size and friability, they might produce only low-grade obstruction. As a result, although serum bilirubin or transaminases are not reliably associated with CDL in SCD,⁴⁶ incremental hyperbilirubinemia (with levels more than 5 mg/dL) is a better predictor of CDL than is bile duct dilatation or

elevation in either alkaline phosphatase or serum aminotransferase levels.⁴⁷ This differs from cholesterol CDL in which biliary duct dilatation and elevated serum alkaline phosphatase level are good noninvasive predictors. SCD might rarely cause ischemic cholangiopathy characterized by multiple stenoses and dilations of the intrahepatic bile ducts.⁴⁸

Cholecystitis presents with abdominal pain, nausea and vomiting, fever, and/or jaundice, a constellation of symptoms that has multiple possible etiologies in SCD. Symptoms of acute cholecystitis and/or biliary tract obstruction might be due to vascular lesions.⁴⁹

Cholecystectomy is the most frequent surgery in patients with SCD, comprising almost 40% of the procedures on SC patients.⁵⁰ Some authors advocate early cholecystectomy in asymptomatic patients for several reasons. First, emergency surgery might lead to complications such as SC crisis, longer hospital stay, and long operative time required to remove a diseased gallbladder.^{44,51} Histopathologic chronic cholecystitis does not correlate with clinical symptoms.⁵² Furthermore, one study reported no serious complications in their patients undergoing elective cholecystectomy.⁵³ In addition, SC patients



Figure 3. A 40-year-old woman with SC anemia presents with right upper quadrant abdominal pain. Ultrasound of the abdomen demonstrates numerous mobile, echogenic gallstones with dense posterior acoustic shadowing, consistent with pigmented gallstones.

are living longer, and medical management is simplified by eliminating gallstones as a diagnostic possibility. The use of laparoscopic cholecystectomy in this high-risk patient population decreases hospital time without increasing complications.^{54,55}

In contrast, other authors believe that patients with silent gallstones might not develop symptomatic biliary tract disease and that prophylactic cholecystectomy might be associated with an equal or higher mortality rate than postponing surgery until symptoms develop.^{56,57} The perioperative mortality rate of elective cholecystectomy has been reported to be 1% and the rate of postoperative complications to be more than 30%.^{50,54}

Preparation of the patient before surgery and management during and after the operation are essential. Changes in oxygen tension, pH, osmolality, and hydration might trigger the sickling of erythrocytes. Early ambulation and humidified oxygen are essential postoperatively to avoid atelectasis that might lead to sickling within the pulmonary circulation. A conservative transfusion regimen designed to increase the Hb level to 10 g/dL is as effective as an aggressive regimen designed to decrease the Hb S level to less than 30% and with fewer transfusion reactions.⁵⁰ Exchange transfusions that avoid the potential for hyperviscosity from overtransfusion are currently the preferred method for increasing the hematocrit level preoperatively.

Rare Complications of Sickle Cell Disease

The abdominal crisis is due to small infarcts of the mesentery and abdominal viscera causing severe abdominal pain, signs of peritoneal irritation, and a plain film often showing a generalized ileus. The clinical picture might be indistinguishable from other acute abdominal diseases.

Acute pancreatitis might develop in the absence of other etiologies, perhaps as a result of microvascular occlusion and ischemic injury. Patients with acute pancreatitis might develop pulmonary symptoms caused by acute chest syndrome or the pancreatitis itself.

Peptic ulcer disease is found in 35% of patients with SCD and epigastric pain.⁵⁸ Interestingly, duodenal ulcers are not associated with high acid outputs.^{58,59} This suggests that these ulcers might, instead, be due to reduced mucosal resistance, possibly from ischemia.⁵⁸

An uncommon complication is ischemic bowel caused by intravascular sickling, resulting in microvascular occlusion.⁶⁰ Sickle cell crisis might represent a shock equivalent causing vascular spasm and ischemic necrosis. One report documented fatal small bowel necrosis with hypotension.⁶¹ The rarity of ischemic bowel in SCD might be due to the extensive collateral circulation in the mesentery and bowel wall. Abdominal pain of presumed vaso-occlusive origin, often termed "girdle syndrome" because of the circumferential distribution of the pain, rarely presents as ischemic colitis.⁶²

Pseudomembranous colitis without *Clostridium difficile* has been associated with SCD and treated with exchange transfusions.⁶³ Abnormal hydrogen breath tests might reflect disordered gastrointestinal motility or abnormalities of intestinal microflora.⁶⁴

Laboratory Diagnosis

Abdominal pain is very common in SCD and is usually due to sickling, which resolves with supportive care. These acute complications often need just clinical examination, basic blood tests, and sometimes an abdominal ultrasound. Any fever should be evaluated, although it might just be due to the vaso-occlusive crisis.

An elevated bilirubin level, mostly unconjugated, is the most common laboratory abnormality. This represents an increased load of erythrocyte breakdown products on an acutely damaged liver.⁶⁵ Marked hyperbilirubinemia with only mild elevation of ALT and normal coagulation profiles might occur with minimal to no symptoms.⁶⁶ This hyperbilirubinemia resolves spontaneously within weeks. There is some enhancement of bilirubin conjugation in patients with SCD as a result of bilirubin induction of uridine diphosphate-glycuronyltransferase, which is elevated in these patients.⁶⁷ Bilirubin and lactate dehydrogenase (LDH) levels correlate with one another, suggesting that chronic hemolysis and ineffective erythropoiesis, rather than liver disease, are the sources of hyperbilirubinemia. There is a correlation between AST and LDH, indicating some contribution of erythrocyte AST from hemolysis to the serum levels of AST.¹¹ In addition, AST elevation might be partly due to muscle breakdown because there is a concomitant elevation of creatine phosphokinase. Thus, hepatocyte injury is better reflected by an increase in ALT, rather than AST, levels. Alkaline phosphatase level is commonly elevated particularly during pain crises mainly as a result of bone rather than liver isoenzymes.⁶⁸ This is further shown by the correlation of serum 5' nucleotidase elevations with γ -glutamyltransferase, but not with increases in alkaline phosphatase level.⁶⁹

Ferritin levels correlate with liver iron concentrations in some studies⁷⁰ but not others.⁷¹⁻⁷³ Increases in ferritin level during a crisis might be due to inflammation, liver disease, or hemolysis.

Although not frequently ordered, liver spleen scans with technetium (Tc)-99m sulfur colloid might show reduced splenic activity as a result of splenic atrophy⁷⁴ or splenic sequestration.⁷⁵ Splenic infarction might be seen as total or segmental lack of uptake by the spleen.⁴³ Although the spleen might not be visible on Tc-99m sulfur colloid scans, it might instead be seen on bone scan because of multiple infarctions and calcifications.⁴³ In converse, when the spleen is functioning by liver-spleen scan, then it is not seen on bone imaging.⁷⁶

With severe right upper quadrant pain, the Tc-99m diisopropyl-iminodiacetic acid scan might show prolonged nonvisualization of the gallbladder, consistent with acute cholecystitis, or more commonly, delayed visualization consistent with chronic cholecystitis.⁷⁷ Demonstration of the gallbladder on hepatobiliary radionuclide scan effectively excludes acute calculous cholecystitis.

Computed tomography (CT) scan might be ordered in patients with unremitting or severe abdominal pain.^{78,79} Abnormalities in 17 of 30 patients altered treatment, showing liver or splenic disease or basal pulmonary pathology presenting as abdominal pain.⁷⁸ Areas of splenic infarction are seen as low-density lesions.⁷⁹ Sequestration syndrome causes hypoechoic appearance on ultrasound and low attenuation on CT scan⁶ associated with a dramatic drop in Hb levels. Nonenhanced blood vessels on CT scan of the liver are due to increased hepatic density from hemosiderosis and decreased blood density from anemia.⁴³

On magnetic resonance imaging (MRI), liver iron concentration is inversely correlated with T2 values as a result of the

paramagnetic properties of hemosiderin.⁷⁰ Iron shortens the T1 and T2 relaxation times, darkening the images.⁸⁰ The advantage of MRI compared with liver biopsy is its noninvasiveness and low interstudy variability, making it a good tool for serial evaluation of chelation efficacy and simultaneous measurements of cardiac iron levels, although it is expensive. Although MRI can separate those patients with liver iron levels greater or less than 100 $\mu\text{g}/\text{mg}$ of liver, it is unable to differentiate between 100–400 $\mu\text{g}/\text{mg}$.⁸¹ Those with splenomegaly have a hypercellular spleen with hemosiderin and ferritin deposits that decrease the signal intensity. The calcified and fibrotic spleen also has decreased intensity on T1 and T2 weighted images⁴³ (Figure 1).

Areas of functional spleen might appear hypoechoic on ultrasound and low density on CT scan, giving a picture that could be confused with splenic abscesses.⁷⁶ The functional spleen, however, takes up Tc-99m sulfur colloid unlike abscesses. Furthermore, liver abscesses take up gallium or indium 111-labeled white blood cells,⁴³ unlike areas of functional spleen.

In the pancreas, hemosiderin tends to deposit in the acinar cells rather than in the islet cells.⁸² This can cause increased echogenicity. MRI demonstrates a moderate decrease in signal intensity in the pancreas on T1 weighted images and a more marked decrease on T2 weighted images compared with the liver.

Although not usually performed during an acute sickle crisis, a liver biopsy might show prominent aggregations of sickled red cells, Kupffer cell enlargement, and hemosiderosis, perhaps resulting in hypoxia, fibrosis, and repair (Figure 2).⁸ In the absence of splenic function, there is an abnormal propensity of the sickled cells to interact with the macrophages, resulting in erythrophagocytosis.⁸³ However, there is no correlation between the degree of intrahepatic sickling and the transaminase levels. Shrunken hepatocytes or perivenular necrosis, features characteristically seen in ischemic or anoxic livers, are generally not seen in SCD.⁸³ Ischemic necrosis is found in patients in shock or in postmortem examinations; the latter most likely represents agonal anoxia. Cholestasis is common, sometimes as a result of extrahepatic obstruction, but biliary cirrhosis is rare. The safety of liver biopsies has been questioned, especially in those in acute sickling crisis.⁸⁴ Patients with complications from liver biopsy have chronic venous outflow obstruction, marked hepatic sequestration of erythrocytes, and sinusoidal dilatation.

Treatment

Transfusions should be given to correct anemia with Hb below 5 g/dL because Hb S has a low oxygen affinity and achieves good oxygenation despite the anemia.⁸⁵ Urgent transfusion is often required for a sudden severe anemia when blood is sequestered in an enlarging spleen or liver or when parvovirus infection causes a transient aplastic crisis. Patients should not be transfused above their baseline Hb level.

Exchange transfusions, in which patients are given blood at the same time as they are venesected, minimize the sludging and vaso-occlusion caused by an increase in blood viscosity from blood with high packed cell volume. The aim is to decrease the percentage of Hb S to below 20%. Exchange transfusions result in a lower iron load and a slower increase in ferritin levels compared with conventional transfusions.⁸⁵ They are considered in patients with prolonged, refractory vaso-occlusive crises with a stable baseline Hb. Exchange transfusions can also be used for intrahepatic cholestasis along with fresh frozen

plasma to correct any coagulopathy because these interventions can reverse this potentially fatal syndrome.⁸⁶ Chronic intrahepatic cholestasis, a rare event, might be treated with regular exchange transfusions.⁸⁷ Erythrocytapheresis, which removes sickled cells and older erythrocytes, reduces iron accumulation.⁸⁸

Deferoxamine is an iron-chelating agent that causes excretion of iron in the urine and bile, resulting in decreases in serum ferritin and ALT levels.^{37,89} Recently deferasirox and deferiprone have been introduced, with the advantage of oral rather than subcutaneous administration.^{89,90}

Hydroxyurea increases Hb F levels, reducing the frequency of pain crises, lowering transfusion requirements, and causing a return of splenic function as determined by liver-spleen scans.⁹¹ It is used in patients with severe complications, usually non-gastroenterological. Bone marrow or peripheral blood progenitor cell transplantation is mainly done when there is a history of a stroke.⁹²

Cadaveric and living-related donor liver transplantation has been performed in SC patients with liver failure or cirrhosis.^{93,94} Perioperative transfusions were used to keep Hb S levels below 20%–25%. Allogeneic stem cell transplantation can be curative in young patients.⁹⁵ In adults, nonmyeloablative allogeneic hematopoietic stem-cell transplantation can reverse the sickle cell phenotype.⁹⁶

Prognosis

Whether hepatic dysfunction can lead to increased mortality is controversial. Although one study showed no increased risk of death related to liver disease, with only 1% of patients developing fulminant hepatic failure,⁹⁷ others implicated cirrhosis as a direct cause of death in 11% of patients.³⁰ A favorable outcome of fulminant liver failure might occur after exchange transfusions.⁹⁸

References

1. Harmening DM. Clinical hematology and fundamentals of hemostasis. 5th ed. Philadelphia: FA Davis Co, 2009:209–214.
2. Braunwald E, Fauci AS, Kasper DL, et al. Harrison's principles of internal medicine. 15th ed. New York, NY: McGraw-Hill Medical Publishing Division, 2001:669.
3. Yeung K-Y, Lessin LS. Splenic infarction in sickle cell-hemoglobin C disease. *Arch Intern Med* 1976;136:905–911.
4. King DT, Lindstrom RR, State D, et al. Unusual cause of acute abdomen: sickle cell trait and nonhypoxic splenic infarction. *JAMA* 1977;238:2173–2174.
5. Madani G, Papadopoulou AM, Holloway B, et al. The radiological manifestations of sickle cell disease. *Clin Radiology* 2007;62:528–538.
6. Roshkow JE, Sanders LM. Acute splenic sequestration crisis in two adults with sickle cell disease: US, CT, and MR imaging findings. *Radiology* 1990;177:723–725.
7. Koskinas J, Manesis EK, Zacharakis GH, et al. Liver involvement in acute vaso-occlusive crisis of sickle cell disease: prevalence and predisposing factors. *Scand J Gastroenterol* 2007;42:499–507.
8. Bauer TW, Moore GW, Hutchins GM. The liver in sickle cell disease: a clinicopathologic study of 70 patients. *Am J Med* 1980;69:833–837.
9. Mengel CE, Schauble JF, Hammond CB. Infarct-necrosis of the liver in a patient with S-A hemoglobin. *Arch Intern Med* 1963;111:93–98.
10. Fishbone G, Nunez D Jr, Leon R, et al. Massive splenic infarction

- in sickle cell-hemoglobin C disease: angiographic findings. *AJR* 1977;129:927-928.
11. Johnson CS, Omata M, Tong MJ, et al. Liver involvement in sickle cell disease. *Medicine* 1985;64:349-356.
 12. Schubert TT. Hepatobiliary system in sickle cell disease. *Gastroenterology* 1986;90:2013-2021.
 13. Rosenblate HJ, Eisenstein R, Holmes AW. The liver in sickle cell anemia: a clinical-pathologic study. *Arch Pathol* 1970;90:235-245.
 14. Hatton CSR, Bunch C, Weatherall DJ. Hepatic sequestration in sickle cell anaemia. *Br Med J* 1985;290:744-745.
 15. Hernandez P, Dorticos E, Espinosa E, et al. Clinical features of hepatic sequestration in sickle cell anaemia. *Haematologia* 1989;22:169-174.
 16. Lee ES, Chu PC. Reverse sequestration in a case of sickle crisis. *Postgrad Med J* 1996;72:487-488.
 17. Shao SH, Orringer EP. Sickle cell intrahepatic cholestasis: approach to a difficult problem. *Am J Gastroenterol* 1995;90:2048-2050.
 18. Owen DM, Aldridge JE, Thompson RB. An unusual hepatic sequela of sickle cell anemia: a report of five cases. *Am J Med Sci* 1965;249:175-185.
 19. Garcia-Arias MB, Rodriguez-Galindo C, Hoffer FA, et al. Pyogenic hepatic abscess after percutaneous liver biopsy in a patient with sickle cell disease. *J Pediatr Hematol/Oncol* 2005;27:103-105.
 20. Shulman ST, Beem MO. An unique presentation of sickle cell disease: pyogenic hepatic abscess. *Pediatrics* 1971;47:1019-1022.
 21. Robins-Browne RM, Prpic JK. Desferrioxamine and systemic yersiniosis. *Lancet* 1983;2:1372.
 22. Sheehy TW. Sickle cell hepatopathy. *South Med J* 1977;70:533-538.
 23. DeVault KR, Friedman LS, Westerberg S, et al. Hepatitis C in sickle cell anemia. *J Clin Gastroenterol* 1994;18:206-209.
 24. Mok Q, Underhill G, Wonke B, et al. Intrahepatic hepatitis B vaccine in thalassaemia and sickle cell disease. *Arch Dis Child* 1989;64:535-540.
 25. Middletown JP, Wolper JC. Hepatic biloma complicating sickle cell disease: a case report and a review of the literature. *Gastroenterology* 1984;86:743-744.
 26. Saltzman JR, Johnston DE. Sickle cell crisis and cocaine hepatotoxicity. *Am J Gastroenterol* 1992;87:1661-1663.
 27. Sty RJ. Ultrasonography: hepatic vein thrombosis in sickle cell anemia. *Am J Pediatr Hematol-Oncol* 1982;4:213-215.
 28. Arnold KE, Char G, Serjeant GR. Portal vein thrombosis in a child with homozygous sickle cell disease. *West India Med J* 1993;42:27-28.
 29. Berry PA, Cross TJ, Thein SL, et al. Hepatic dysfunction in sickle cell disease: a new system of classification based on global assessment. *Clin Gastroenterol Hepatol* 2007;5:1469-1476.
 30. Darbari DS, Kple-Faget P, Kwagyan J, et al. Circumstances of death in adult sickle cell disease patients. *Am J Hematol* 2006;81:858-863.
 31. Ayyub MA, El-Moursy SA, Khazindar AM, et al. Successful treatment of chronic hepatitis C virus infection with peginterferon alpha-2a and ribavirin in patients with sickle cell disease. *Saudi Med J* 2009;30:712-716.
 32. Ancel D, Amiot X, Chaslin-Ferbus D, et al. Treatment of chronic hepatitis C in sickle cell disease and thalassaemic patients with interferon and ribavirin. *Eur J Gastroenterol Hepatol* 2009;21:726-729.
 33. Telfer PT, Garson JA, Whitby K, et al. Combination therapy with interferon alpha and ribavirin for chronic hepatitis C virus infection in thalassaemic patients. *Br J Haematol* 1997;98:850-855.
 34. Markowitz RI, Harcke HT, Ritchie WG, et al. Focal nodular hyperplasia of the liver in a child with sickle cell anemia. *AJR* 1980;134:594-597.
 35. Al-Mukhaizeem KA, Lamoureux E, Rosenberg A, et al. Nodular regenerative hyperplasia of the liver and focal glomerulosclerosis associated with sickle cell anemia. *Dig Dis Sci* 2002;47:443-447.
 36. Yuzbasiyan-Gurkan VA, Brewer GJ, Vander AJ, et al. Net renal tubular reabsorption of zinc in healthy man and impaired handling in sickle cell anemia. *Am J Hematol* 1989;31:87-90.
 37. Silliman CC, Peterson VM, Mellman DL, et al. Iron chelation by deferoxamine in sickle cell patients with severe transfusion-induced hemosiderosis: a randomized, double-blind study of the dose-response relationship. *J Lab Clin Med* 1993;122:48-54.
 38. Prasad AS, Rabbani P, Warth JA. Effect of zinc on hyperammone-mia in sickle cell anemia subjects. *Am J Hematol* 1979;7:323-327.
 39. Prasad AS, Beck FW, Kaplan J, et al. Effect of zinc supplementation on incidence of infections and hospital admissions in sickle cell disease. *Am J Hematol* 1999;61:194-202.
 40. Bond LR, Hatty SR, Horn MEC, et al. Gallstones in sickle cell disease in the United Kingdom. *Br Med J* 1987;295:234-236.
 41. Rennels MB, Dunne MG, Grossman NJ, et al. Cholelithiasis in patients with major sickle hemoglobinopathies. *Am J Dis Child* 1984;138:66-67.
 42. Sarnaik S, Slovis TL, Corbett DP, et al. Incidence of cholelithiasis in sickle cell anemia using the ultrasonic gray-scale technique. *J Pediatr* 1980;96:1005.
 43. Rao VM, Mapp EM, Wechsler RJ. Radiology of the gastrointestinal tract in sickle cell anemia. *Semin Roentgenol* 1987;22:195-204.
 44. Stephens CG, Scott RB. Cholelithiasis in sickle cell anemia: surgical or medical management. *Arch Intern Med* 1980;140:648-651.
 45. Ware RE, Schultz WH, Filston HC, et al. Diagnosis and management of common bile duct stones in patients with sickle hemoglobinopathies. *J Pediatric Surg* 1992;27:572-575.
 46. Ware R, Filston HC, Schultz WH, et al. Elective cholecystectomy in children with sickle hemoglobinopathies. *Ann Surg* 1988;208:17-22.
 47. Gholson CF, Grier JF, Ibach MB, et al. Sequential endoscopic/laparoscopic management of sickle hemoglobinopathy-associated cholelithiasis and suspected choledocholithiasis. *South Med J* 1995;88:1131-1135.
 48. Hillaire S, Gardin C, Attar A, et al. Cholangiopathy and intrahepatic stones in sickle cell disease: coincidence or ischemic cholangiopathy? *Am J Gastroenterol* 2000;95:300-301.
 49. Charlotte F, Bachir D, Nenert M, et al. Vascular lesions of the liver in sickle cell disease: a clinicopathological study in 26 living patients. *Arch Pathol Lab Med* 1995;119:46-52.
 50. Vichinsky EP, Haberkern CM, Neumayr L, et al. A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. *N Engl J Med* 1995;333:206-213.
 51. Curro G, Meo A, Ippolito D, et al. Asymptomatic cholelithiasis in children with sickle cell disease: early or delayed cholecystectomy? *Ann Surg* 2007;245:126-129.
 52. Suell MN, Horton TM, Dishop MK, et al. Outcomes for children with gallbladder abnormalities and sickle cell disease. *J Pediatr* 2004;145:617-621.
 53. Meshikhes AW, Al-Abkari HA, Al-Faraj AA, et al. The safety of laparoscopic cholecystectomy in sickle cell disease: an update. *Ann Saudi Med* 1998;18:12-14.
 54. Haberkern CM, Neumayr LD, Orringer EP, et al. Cholecystectomy in sickle cell anemia patients: perioperative outcome of 364 cases from the National Preoperative Transfusion Study. *Blood* 1997;89:1533-1542.
 55. Al-Mulhim AS, Al-Mulhim FM, Al-Suwaiygh AA. The role of laparoscopic cholecystectomy in the management of acute cholecystitis in patients with sickle cell disease. *Am J Surg* 2002;183:668-672.
 56. Rutledge R, Croom RD, Davis JW, et al. Cholelithiasis in sickle cell anemia: surgical considerations. *South Med J* 1886;79:28-30.

57. Manno CS, Cohen AR, Schwartz E. Sick cell anemia and cholelithiasis. *Pediatr Radiol* 1988;18:178.
58. Lee MG, Thirumalai CH, Terry SI, et al. Endoscopic and gastric acid studies in homozygous sickle cell disease and upper abdominal pain. *Gut* 1989;30:569–572.
59. Wosornu L, Konotey-Ahulu. Gastric acid secretion in sickle cell anaemia. *Gut* 1971;12:197–199.
60. Gage TP, Gagnier JM. Ischemic colitis complicating sickle cell crisis. *Gastroenterology* 1983;84:171–174.
61. Hammond TG, Mossesson MW. Fatal small-bowel necrosis and pulmonary hypertension in sickle cell disease. *Arch Intern Med* 1989;149:147–148.
62. Qureshi A, Lang N, Bevan DH. Sick cell “girdle syndrome” progressing to ischaemic colitis and colonic perforation. *Clin Lab Haematol* 2006;28:60–62.
63. Baruchel S, Delifer JC, Sigalet D, et al. Pseudomembranous colitis in sickle cell disease responding to exchange transfusion. *J Pediatr* 1992;121:915–917.
64. Heyman MB, Lande W, Vichinsky E, et al. Elevated fasting breath hydrogen and abnormal breath tests in sickle cell disease: a preliminary report. *Am J Clin Nutr* 1989;49:654–657.
65. Barrett-Connor E. Sick cell and viral hepatitis. *Ann Intern Med* 1968;69:517–527.
66. Buchanan GR, Glader BE. Benign course of extreme hyperbilirubinemia in sickle cell anemia: analysis of six cases. *J Pediatr* 1977;91:21–24.
67. Maddrey WC, Cukier JO, Maglalang AC, et al. Hepatic bilirubin UDP-glucuronyltransferase in patients with sickle cell anemia. *Gastroenterology* 1978;74:193–195.
68. Brody JI, Ryan WN, Haidar MA. Serum alkaline phosphatase isoenzymes in sickle cell anemia. *JAMA* 1975;232:738–741.
69. Mohamed AO, Jansson A, Ronquist G. Increased activity of 5'-nucleotidase in serum in patients with sickle cell anaemia. *Scand J Clin Lab Invest* 1993;53:701–704.
70. Voskaridou E, Douskou M, Terpos E, et al. Magnetic resonance imaging in the evaluation of iron overload in patients with beta thalassaemia and sickle cell disease. *Br J Haematol* 2004;126:736–742.
71. Brittenham GM, Cohen AR, McLaren CE, et al. Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. *Am J Hematol* 1993;42:81–85.
72. Harmatz P, Butensky E, Quirolo K, et al. Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy. *Blood* 2000;96:76–79.
73. Brownell A, Lowson S, Brozovic M. Serum ferritin concentration in sickle cell crisis. *J Clin Pathol* 1986;39:253–255.
74. Silberstein EB, DeLong S, Cline J. Tc-99m diphosphonate and sulfur colloid uptake by the spleen in sickle disease: interrelationship and clinical correlates—concise communication. *J Nucl Med* 1984;25:1300–1303.
75. Geola F, Kukreja SC, Schade SG. Splenic sequestration with sickle cell-C disease. *Arch Intern Med* 1978;138:307–308.
76. Levin TL, Berdon WE, Haller JO, et al. Intrasplenic masses of “preserved” functioning splenic tissue in sickle cell disease: correlation of imaging findings (CT, ultrasound, MRI, and nuclear scintigraphy). *Pediatr Radiol* 1996;26:646–649.
77. D'Alonzo WA Fr, Heyman S. Biliary scintigraphy in children with sickle cell anemia and acute abdominal pain. *Pediatr Radiol* 1985;15:395–398.
78. Magid D, Fishman EK, Charache S, et al. Abdominal pain in sickle cell disease: the role of CT. *Radiology* 1987;163:325–328.
79. Magid D, Fishman EK, Siegelman SS. Computed tomography of the spleen and liver in sickle cell disease. *Am J Roentgenol* 1984;143:245–249.
80. Wood JC, Enriquez C, Ghugre N, et al. MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. *Blood* 2005;106:1460–1465.
81. Hernandez RJ, Sarnaik SA, Lande I, et al. MR evaluation of liver iron overload. *J Comp Assisted Tomography* 1988;12:91–94.
82. Flyer MA, Haller JO, Sundaram R. Transfusional hemosiderosis in sickle cell anemia: another cause of an echogenic pancreas. *Pediatr Radiol* 1993;23:140–142.
83. Omata M, Johnson CS, Tong M, et al. Pathological spectrum of liver diseases in sickle cell disease. *Dig Dis Sci* 1986;31:247–256.
84. Zakaria N, Knisely A, Portmann B, et al. Acute sickle cell hepatopathy represents a potential contraindication for percutaneous liver biopsy. *Blood* 2003;101:101–103.
85. Porter JB, Huehns ER. Transfusion and exchange transfusion in sickle cell anaemias, with particular reference to iron metabolism. *Acta Haematol* 1987;78:198–205.
86. Sheehy TW, Law DE, Wade BH. Exchange transfusion for sickle cell intrahepatic cholestasis. *Arch Intern Med* 1980;140:1364–1365.
87. O'Callaghan A, O'Brien SG, Ninkovic M, et al. Chronic intrahepatic cholestasis in sickle cell disease requiring exchange transfusion. *Gut* 1995;37:144–147.
88. Adams DM, Schultz WH, Ware RE, et al. Erythrocytapheresis can reduce iron overload and prevent the need for chelation therapy in chronically transfused pediatric patients. *J Pediatr Hematol Oncol* 1996;18:46–50.
89. Vichinsky E, Onyekwere O, Porter J, et al. A randomized comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. *Br J Hematol* 2006;136:501–508.
90. Voskaridou E, Douskou M, Terpos E, et al. Deferiprone as an oral iron chelator in sickle cell disease. *Ann Hematol* 2005;84:434–440.
91. Claster S, Vichinsky E. First report of reversal of organ dysfunction in sickle cell anemia by the use of hydroxyurea: splenic regeneration. *Blood* 1996;88:1951–1953.
92. Bernaudin F. Results and current indications of bone marrow allograft in sickle cell disease. *Pathol Biol* 1999;47:59–64.
93. Lerut JP, Claeys N, Laterre PF, et al. Hepatic sickling: an unusual cause of liver allograft dysfunction. *Transplantation* 1999;67:65–68.
94. Emre S, Schwartz ME, Shneider B, et al. Living related liver transplantation for acute liver failure in children. *Liver Transpl Surg* 1999;5:161–165.
95. Walters MC, Patience M, Leisenring W, et al. Bone marrow transplantation for sickle cell disease. *N Engl J Med* 1996;335:369–376.
96. Hsieh MM, Kang EM, Fitzhugh CD, et al. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. *N Engl J Med* 2009;361:2309–2317.
97. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease: life expectancy and risk factors for early death. *N Engl J Med* 1994;330:1639–1644.
98. Stephan JL, Merpit-Gonon E, Richard O, et al. Fulminant liver failure in a 12-year-old girl with sickle cell anaemia: favourable outcome after exchange transfusions. *Eur J Pediatr* 1995;154:469–471.

Reprint requests

Address requests for reprints to: Ellen C. Ebert, MD, UMDNJ, 1 RWJ Place, New Brunswick, New Jersey 08901. e-mail: ebertec@umdnj.edu; fax: (732) 235-7792.

Conflicts of interest

The authors disclose no conflicts.